[{"id":"63838d90-f82c-44d3-afff-603ca5347be5","acronym":"EPOCH","url":"https://clinicaltrials.gov/study/NCT05619913","created_at":"2023-11-28T05:15:42.216Z","updated_at":"2025-02-25T13:36:18.599Z","phase":"Phase 2","brief_title":"EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma","source_id_and_acronym":"NCT05619913 - EPOCH","lead_sponsor":"Australia New Zealand Gynaecological Oncology Group","biomarkers":" HMGA2","pipe":" | ","alterations":" HMGA2 expression","tags":["HMGA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HMGA2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Halaven (eribulin mesylate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-04"}]